Last update 23 Jan 2025

Actavis South Atlantic LLC

Subsidiary Company|
New Jersey, United States

Overview

Tags

Neoplasms
Immune System Diseases
Endocrinology and Metabolic Disease
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Endocrinology and Metabolic Disease1
Hemic and Lymphatic Diseases1
Immune System Diseases1
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
Tubulin1
DNMT1(DNA (cytosine-5)-methyltransferase 1)1

Related

3
Drugs associated with Actavis South Atlantic LLC
Cabazitaxel Acetone
Target
Tubulin
Mechanism
Tubulin inhibitors
Active Org.
Sanofi KK [+12]
Originator Org.
SanofiSanofi
Active Indication
Prostatic Cancer [+8]
Inactive Indication
Adenocarcinoma of Esophagus [+29]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date17 Jun 2010
Azacitidine
Target
DNMT1
Mechanism
DNMT1 inhibitors [+1]
Active Org.
AbbVie, Inc.AbbVie, Inc. [+18]
Originator Org.
Celgene Corp.Celgene Corp.
Active Indication
Juvenile Myelomonocytic Leukemia [+51]
Inactive Indication
Acute myeloid leukaemia with 11q23 abnormality [+61]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date19 May 2004
Levofolinate Calcium
Target
TYMS
Mechanism
TYMS inhibitors [+1]
Active Org.
Pfizer Japan, Inc.Pfizer Japan, Inc. [+1]
Originator Org.
Pfizer Japan, Inc.Pfizer Japan, Inc.
Active Indication
Small intestine carcinoma [+3]
Inactive Indication
Drug intoxication [+6]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
JP
First Approval Date16 Jun 1999
2
Clinical Trials associated with Actavis South Atlantic LLC
CTRI/2015/05/005737
/ CompletedNot Applicable
A multicenter, randomized, open label, two treatment, two period,two sequence, single-dose, crossover, bioequivalence study ofMethotrexate Tablets 2.5 mg (manufactured for Actavis LLC) withMethotrexate Tablets USP 2.5 mg (DAVA Pharmaceuticals, Inc.,Fort Lee, NJ 07024 USA) in patients with mild to severe psoriasisor rheumatoid arthritis (RA), who are already on establishedregimens of 2.5 mg every 12 hours under fasting condition. - NA
CTRI/2015/03/005653
/ RecruitingNot Applicable
A randomized, open label, multi centric, two treatment, two period, two sequence, single dose, crossover, bioequivalence study of Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 100 mg/vial manufactured by Sindan Pharma for Actavis LLC, USA and Abraxane 100 mg/vial (Albumin bound Paclitaxel 260 mg/m2) intravenous infusion Abraxis BioScience LLC, New Jersey in patients with metastatic breast cancer
100 Clinical Results associated with Actavis South Atlantic LLC
Login to view more data
0 Patents (Medical) associated with Actavis South Atlantic LLC
Login to view more data
100 Deals associated with Actavis South Atlantic LLC
Login to view more data
100 Translational Medicine associated with Actavis South Atlantic LLC
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
2
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Cabazitaxel Acetone
 ( Tubulin )		Metastatic castration-resistant prostate cancer
More
Approved
Azacitidine
 ( DNMT1 )		Myelodysplastic Syndromes
More
Approved
Levofolinate Calcium
 ( TYMS )		Osteosarcoma
More
Withdrawn
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free